Evidence mapPaperPMID 42450989Full record

ReviewHealthcare (Basel, Switzerland)2026

Glycemic Variability and Continuous Glucose Monitoring in Occupational Health: A Narrative Review of Emerging Evidence and Potential Applications in Working Populations.

Aikaterini Andreadi, Stella Andreadi, Federica Todaro, Marco Cerilli, Pietro Lodeserto, Giuseppe Pinto, Marco Meloni, Alfonso Bellia, Luca Coppeta, Andrea Magrini and 2 more

Abstract readReview
In one paragraph

Review in Healthcare (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aikaterini AndreadiSection of Endocrinology and Metabolic Diseases, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-2294-5833
Stella AndreadiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0009-0008-6107-0324
Federica TodaroSection of Endocrinology and Metabolic Diseases, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-6544-193X
Marco CerilliEndocrinology and Diabetology Clinic, Department of Medical Sciences, Foundation Policlinico Tor Vergata, 00133 Rome, Italy.
Pietro LodesertoSection of Endocrinology and Metabolic Diseases, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Giuseppe PintoSection of Endocrinology and Metabolic Diseases, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Marco MeloniSection of Endocrinology and Metabolic Diseases, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-3789-9622
Alfonso BelliaSection of Endocrinology and Metabolic Diseases, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Luca CoppetaDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-2470-6107
Andrea MagriniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
George P ChrousosUniversity Research Institute of Maternal and Child Health and Precision Medicine, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-3098-5264
Davide LauroSection of Endocrinology and Metabolic Diseases, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-8597-4415

Funding

Funded by the European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS Policlinico Tor Vergata, PNRR-POC-2022-12376842, Role of Peroxiredoxin- 6 as New Insulin and GLP-1 Secretagogue PNRR-POC-2022-12376842
6 · The paper itself

Abstract

backgroundFasting plasma glucose, glycated hemoglobin (HbA1c), and oral glucose tolerance testing remain central to the diagnosis and monitoring of dysglycemia, but they mainly reflect the average glycemic exposure or discrete time-point measurements and may not capture intraday and interday glucose fluctuations. Glycemic variability (GV) has been associated with oxidative stress, endothelial dysfunction, inflammation, and diabetes-related complications, although much of the evidence derives from experimental, clinical, and diabetes-care settings rather than occupational cohorts.

aimThis narrative review examines the physiological basis, measurement, and potential occupational relevance of GV and continuous glucose monitoring (CGM) in working populations.

methodsLiterature was narratively selected from biomedical databases, major guidelines, consensus statements, and occupational-health sources, prioritizing reviews, clinical guidelines, cohort studies, mechanistic studies, and CGM studies. No systematic search, risk-of-bias assessment, or quantitative synthesis was performed. MAIN

findingsCGM is an established technology in selected diabetes-care contexts and provides metrics such as coefficient of variation, time in range, time above range, and time below range. Its use in occupational medicine, however, remains investigational outside selected clinical circumstances. Work-related factors such as shift work, circadian disruption, sleep loss, psychosocial stress, irregular meal timing, sedentary behavior, and variable physical workload may influence glucose regulation, but direct evidence linking these exposures to CGM-measured GV in workers remains limited. IMPLICATIONS: Potential applications include research on occupational determinants of metabolic health, monitoring of workplace lifestyle interventions, and individualized management of workers with diabetes in safety-sensitive roles, provided that consent, confidentiality, clinical follow-up, equity, and data-governance safeguards are ensured.

conclusionsGV assessment may complement traditional metabolic markers in selected occupational-health contexts, but routine CGM-based surveillance of general worker populations is not currently supported by sufficient evidence. Further longitudinal and interventional studies are required.

Indexed as

continuous glucose monitoringglycemic variabilityoccupational healthworker health surveillance

Identifiers

PMID42450989
PMCPMC13360620

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.